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Abstract
Antimicrobial resistance results in substantial adverse 
outcomes and negatively impacts mortality, morbidity and 
economic expenditure. This review focuses on the costs of 
antibiotic resistance to both patient as well as health-care settings 
and highlights interventions proven to be effective in curtailing 
its continued escalation. These concentrate predominantly on 
initiatives to improve antibiotic prescribing as well as prevent 
the spread of multi-resistant organisms, amongst which hand 
hygiene is of paramount importance. With the prevalence 
of resistance in Malta, amongst the highest in Europe, such 
interventions need acceptance and implementation by all 
stakeholders if the current alarming situation is to be controlled 
and possibly improved.
Introduction 
Antimicrobial resistance is increasing and brings with it 
the possibility of untreatable infections and a return to the 
pre-antibiotic era.1 This phenomenon impinges on the quality 
of patient care through its associated mortality, morbidity 
and economic consequences. It also forces upon us the need 
to resort to more expensive and toxic antibiotics and develop 
new products to replace those which have been rendered 
ineffective.2
The threat of antimicrobial resistance has been identified 
as one of the major challenges facing public health by 
numerous scientific organisations, including the World Health 
Organization.3 The challenge of the “Microbial Threat” is even 
recognised by the European Union (EU) through numerous 
communications over the past years culminating in the adoption 
of a community approach titled ‘A strategy against the Microbial 
Threat’ which was approved through the EU Council Resolution 
of the 8th of June 1999.4 
The impact of antibiotic resistance
Antibiotic resistance impacts adversely on the ability to 
provide effective management of infectious diseases, whether 
they arise in the hospital or in the community. A meta-analysis 
of 31 published studies over 20 years identified an almost 
two-fold increased risk of mortality in methicillin resistant 
Staphylococcus aureus (MRSA) bacteraemia as opposed to 
the same infection caused by sensitive strains of the identical 
organism.5 One major reason for this finding stems from the 
need to provide timely and targeted antimicrobial therapy for 
patients suffering from serious infections. The administration 
of effectives doses of the correct antibiotic as early as possible in 
the course of an infection is one of the major predictors of cure.6 
It is much more likely that empiric treatment would fail in an 
environment where there is a high prevalence of antimicrobial 
resistance, resulting in significant delay to provide effective 
therapy and leading to worsened outcomes.7,8,9 In addition, 
antimicrobial alternatives for resistant organisms often carry 
significant side effects. This is particularly the case with 
glycopeptides used in the treatment of MRSA and both colistin 
and tobramycin which may be required for resistant Gram-
negative organisms.10,11 Furthermore, scenarios of potentially 
untreatable infections are already unfolding within both Gram 
positive bacteria such as enterococci and in Gram-negative 
bacilli, including pan-resistant Acinetobacter spp.1 
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Effect of antimicrobial resistance 
on healthcare facilities 
The repercussions of resistance are not simply restricted 
to the individual patient. Resistance also has direct impact on 
health-care facilities.12 Patients with resistant infections need 
longer duration of hospitalisation to treat their nosocomial 
infection.13 This in turn impacts on the efficient running of 
hospitals, blocking beds and limiting throughput. Not only do 
patients with resistant infections utilise precious bed space 
and require additional expenses related to the hotel functions 
of a hospital but they invariably require treatment with more 
expensive antibiotics, which adds another financial element 
into the equation.14 It is therefore not surprising that the cost of 
antibiotic resistance to society as a whole is very significant. In 
1995, the national cost of resistance for the United States was 
estimated to approximate four billion dollars per year.15 This 
figure is now likely to be substantially higher. 
Antimicrobial resistance and antibiotic use
The direct link between antibiotic use and the subsequent 
development of resistance in hitherto sensitive strains of 
bacteria has long been acknowledged. Bacteria can become 
resistant to an antibiotic during exposure to that drug.16 The 
factors that play a role within this process are highly complex 
and often difficult to predict. S. aureus develops resistance to 
vancomycin at very low frequency yet resistant strains rapidly 
follow the use of daptomycin, which is reasonably related.17 
Furthermore, it is not only the antibiotic class that appears 
to be relevant. The total level of antibiotic consumption in 
an institution also seems to be linked to the development of 
resistance. This has been shown through meta-analyses that 
have identified a strong relationship between MRSA prevalence 
and consumption levels.18 It is therefore logical to conclude 
that attempts to reduce resistance should focus on reducing 
unnecessary use of antibiotics. Since acquisition of resistance 
in organisms exposed to narrow spectrum drugs is usually low, 
it is especially important to focus efforts on broad spectrum 
classes which are known to predispose most to resistance 
development.19, 20
Encouraging better use of antibiotics 
Although the actual details of antibiotic stewardship 
programmes differ from one institution to another, two core 
strategies seem to be most effective.21 These include Prospective 
Audit with intervention and feedback as well as a system of Prior 
Authorisation of antibiotic prescribing. Prospective auditing 
involves designated and trained members of an antibiotic 
team, who review patients on antibiotic therapy and provide 
unsolicited feedback to prescribers as to the appropriateness of 
their decisions. This approach has been shown to have numerous 
benefits. It retains the autonomy of prescribers and can be 
customised to the individual institution. If performed by open-
minded individuals, it also stimulates education on antibiotic 
use and most importantly encourages interaction between 
colleagues. The disadvantage lies precisely in its voluntary 
nature; it requires an underlying culture of teamwork in order 
to succeed. Nevertheless in the right environments it has been 
shown to be very effective to improve appropriate antibiotic 
therapy, resulting in diminished use of broad spectrum agents 
as well as reduced expenditure, all without impacting adversely 
on patient outcomes.22
The second strategy focuses on enforced pre-authorisation 
of designated wide spectrum antibiotics. In such a programme, 
infectious disease and microbiology specialists would need 
to be contacted whenever certain antimicrobials (the span of 
restricted antibiotic classes differs between institutions) would 
be requested for treatment. Such a request would then be 
discussed between prescriber and endorser and if not deemed to 
be evidence based, replaced by a more appropriate alternative. 
Efforts to cut down on unnecessary glycopeptides use following 
outbreaks or significant increases in vancomycin resistant 
enterococci (VRE) have been shown to be successful.23 Similar 
restrictions on the use of third generation cephalosporins 
in response to outbreaks of ceftazidime resistant Klebsiella 
pneumoniae, resulted in both an immediate as well as sustained 
reduction in resistant strains.24
Nevertheless, simply cutting down on antibiotic use is not 
a simple panacea for all the problems posed by multi-resistant 
infections. The most convincing evidence for such initiatives 
relates to the prevention of Clostridium difficile diarrhoea, 
where a level of sustained improvement has been identified 
following antibiotic prescribing interventions. On the other 
hand, out of ten investigated prescribing interventions aimed 
at reducing resistant Gram-negative bacteria, only one study 
showed changes that were likely to be clinically relevant. 
Very limited data are additionally available on the impact of 
prescribing interventions on Gram positive bacteria, including 
VRE and MRSA. 25
The need for infection prevention 
and control in healthcare settings
These results suggest that antimicrobial control on its own 
is unlikely to be enough to fully achieve the desired endpoint. 
It is clear that in order to address the problem of antimicrobial 
resistance, efforts need to also simultaneously target the spread 
of resistant organisms within health-care facilities. In fact it 
has been shown that, except when colonisation pressure is 
low, antibiotic consumption only has a moderate effect on the 
prevalence of VRE and possibly other resistant infections.25 The 
major predictor of acquisition is actually the number of colonised 
patients. This is because a greater number of colonised patients 
will lead to more contacts with the hands of health-care workers 
and therefore a greater possibility of cross transmission. 
As a result, it is important to focus on the possible ways by 
which resistant organisms can be spread within a health-care 
facility and utilise this information to implement appropriate 
prevention and control strategies. The role of hands in the 
transmission of health-care associated infections has been 
known since 1847 when Semmelweiss reduced maternal 
mortality rates from puerperal fever in Vienna by simply forcing 
doctors to wash their hands before delivery.26 In the intervening 
150 years we have come to understand that hands of health-care 
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workers regularly become contaminated by micro-organisms 
which originate from the patients with whom they come into 
direct contact.27 Furthermore there is clear evidence that these 
same organisms can also survive for substantial periods of 
time in the environment where they would act as a recurrent 
seed to again contaminate the hands of care providers.28 Multi-
resistant organisms such as MRSA and VRE have been isolated 
consistently both from the hands of health care workers as well 
as environmental locations which are subject to regular contact 
by those same hands.29
Efforts to prevent the spread of clonal multi-resistant 
organisms therefore need to concentrate on breaking the chain 
of transmission from the colonised or infected patients to other 
susceptible individuals via hands of health care workers. In 
theory this can be implemented by isolation precautions for 
all identified or presumptive patients carrying multi-resistant 
organisms and stringent compliance with hand hygiene 
protocols, especially if combined with a proactive screening 
programme. A three phase intervention has been described by 
Harbarth et al. with an initial period of no control measures, 
followed by two years of hand hygiene education, audit and 
feedback and then finally screening and single room isolation. 
The primary initiative stopped what had previously been an 
increasing trend of MRSA infections, which then further reduced 
following the isolation intervention.30 One of the largest meta-
analysis on the subject concluded that concerted efforts which 
focus on isolation can reduce MRSA levels, even in endemic 
circumstances.31 Further expanding on this concept, there are 
additional studies which suggest that a designated isolation ward 
to house patients with multi-resistant pathogens provides the 
most effective results. A retrospective interrupted time series 
study over more than four years suggested that initial isolation 
in single rooms and cohorted beds failed to control MRSA spread 
but a policy change to isolate these cases in a designated separate 
facility resulted in a reduction in incidence, which was sustained 
over a prolonged period.32 
Hand hygiene
Emphasis on improved hand hygiene compliance within 
health care facilities remains a paramount component for all 
infection control programmes and various models have been 
proposed to achieve the desired results. The study that is most 
often quoted in the literature is the one undertaken by Pittet at 
al. in Geneva, Switzerland where improvement in hand hygiene 
compliance through the introduction of alcoholic hand rub 
resulted in an increase of hand hygiene rates from 48% to 66% 
and a concurrent reduction in both overall rates of health care 
associated infections and specifically MRSA transmission.33 
Based to a certain degree on the results of Pittet’s work, alcohol 
hand rub has become the mainstay of the latest recommendations, 
including those issued by the World Health Organization in its 
Clean Care is Safer Care campaign.34 Significant reductions in 
MRSA have been reported following alcohol rub introduction 
and promotion in hospitals.35 In addition to providing more 
convenient facilities, many institutions have also focused their 
efforts to encourage their staff to use those same facilities more 
appropriately and regularly. One way in which this has been 
done is through audits of hand hygiene compliance and feedback 
to the staff being observed. Decrease in health-care associated 
infection prevalence and increase in hand hygiene compliance 
has been reported using such an approach as part of a multi-
modal intervention strategy.36   
Figure 1: Overall proportions of resistance within S. aureus strains isolated at the Microbiology Laboratory of Mater 
Dei Hospital during the year 2008
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Figure 2: Overall proportions of resistance within 
P. aeruginosa strains isolated at the Microbiology 
Laboratory of Mater Dei Hospital during the year 2008
Figure 3: Overall proportions of resistance within E. 
coli strains isolated at the Microbiology Laboratory of 
Mater Dei Hospital during the year 2008
Local antimicrobial resistance epidemiology 
The local state of affairs in Malta appears to be quite 
alarming with various drug-bug combinations exhibiting 
considerable levels of resistance, particularly within health-
care settings. A review of the antimicrobial susceptibility 
data of pathogens isolated at the Microbiology Laboratory of 
Mater Dei Hospital in the year 2008, indicates that the overall 
oxacillin (methicillin) sensitivity of S. aureus strains was only 
37% (Figure 1). In addition, only about half of these isolates 
were sensitive to macrolides, quinolones and fusidic acid, the 
latter almost certainly the consequence of acknowledged abuse 
of topical preparations in the community. Ironically it is the 
older and less popular pharmaceuticals such as tetracyclines, 
lincosamides, nitrofurantoin and co-trimoxazole that show 
the best susceptibility profiles as well as antimicrobials whose 
availability is restricted (glycopeptides and rifampicin).
The situation is just as serious for Pseudomonas aeruginosa, 
typically associated with the most immunocompromised 
patients. Ceftazidime, piperacillin-tazobactam and ciprofloxacin 
– all commonly used agents for such infections – are effective 
for less than 70% of local isolates (Figure 2). Carbapenems, 
so often the final resort, are only marginally superior in 
terms of susceptibility. The preparations that can offer best 
microbiological optimism (tobramycin, amikacin and colistin) 
are in turn characterised by toxic side effects that preclude 
widespread use. Even in the case of Escherichia coli, a pathogen 
not commonly associated with acquired resistance, various 
therapeutic challenges exist. Indeed local strains are already 
substantially unresponsive to commonly used agents, including 
penicillin derivates and fluoroquinolones (Figure 3). 
     A potential criticism of such data is that it includes pooled 
strains, a proportion of which are likely to be colonisers and 
contaminants and therefore clinically insignificant. It is for this 
reason that more attention is being placed upon blood culture 
isolates which, if taken properly, are guaranteed to be relevant. 
Indeed the European Antimicrobial Resistance Surveillance 
System (EARSS: available from www.rivm.nl/earss) utilises 
only such data to provide an epidemiological picture of 
antimicrobial resistance in the European region. Unfortunately, 
the most recent EARSS report highlights Malta as the country 
having the highest proportion of MRSA within the whole 
European network; more than 50% of S. aureus blood culture 
isolates tested methicillin resistant in 2007.37 Furthermore 
trend analysis over the past 8 years suggests a consistent and 
statistically significant increase over this time period (Figure 4). 
Quinolone resistance in E. coli bacteraemia isolates has – like 
MRSA – also increased unabated in the past years, reaching 
levels around 35% in 2007 (Figure 5). Equally worrying is the 
novel appearance, and apparent escalation, of E. coli strains 
that test non-susceptible to third generation cephalosporins. 
This would strongly suggest that highly pathogenic strains are 
rapidly developing extended-spectrum beta-lactamase (ESBL) 
activity, which further decreases therapeutic options in serious 
infections such as septicaemia.
These results are not in themselves genuinely surprising 
since the risk factors identified by this review have already 
been shown to be prevalent in healthcare facilities in this 
country. Per capita antibiotic consumption within tertiary 
care is one of the highest in Europe. Use of wide spectrum 
penicillins, cephalosporins and quinolones is significantly 
higher than equivalent medians at both pan-European and even 
Mediterranean comparison.38 These three groups have been 
implicated as drivers of MRSA as well as ESBL and quinolone 
resistance in Gram-negatives.39 In addition, published data 
support a hypothesis that cross-transmission of resistant 
organisms is being facilitated through inadequate compliance 
with infection control protocols, especially in terms of lack of 
hand hygiene. A recent study reported that overall hand hygiene 
compliance amongst doctors before patient contact was only 
22.7% and ranged as low as 9.9% in some specialties.40 
Conclusion
It is therefore critical to address this escalating situation if 
we are not to be faced with impossible restricted therapeutic 
choices in the treatment of serious infections in the near future. 
This is not the first time that such a call to arms has been made. 
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Very similar conclusions were included in a comprehensive 
multi-stakeholder report issued almost a decade ago.41 The 
recent establishment of a National Antibiotic Committee, with 
legislative backing, promises to provide a base from which 
to kick-start effective interventions aimed at halting, and 
hopefully reversing, this consistent trend of rising antimicrobial 
resistance. 
There is no doubt what those interventions need to be: more 
judicious antibiotic prescribing attitudes together with greater 
ownership and accountability of infection control policies 
and procedures. The way forward is quite obvious; the only 
uncertainty lies in getting all stakeholders to buy into it and 
thereby translate words into day-to-day practice.
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Figure 4: Proportions of methicillin resistance in S. aureus isolates (MRSA) from blood cultures, as reported to the 
European Antimicrobial Resistance Surveillance System network by European countries from 1999 to 2007 (Malta 
= MT); reproduced with permission from EARSS Annual Report 2007. [Only European countries that reported 20 
isolates or more per year for at least three years are included. The arrows indicate significant trends. The asterisks 
indicate significant trends in the overall national data that were, non-significantly, supported by data from laboratories 
reporting all nine years]
Figure 5: Yearly proportions of quinolone and third 
generation cephalosporin resistance in blood culture 
E. coli isolates reported by Malta to the European 
Antimicrobial Resistance Surveillance System network 
between 2000 and 2007; as accessed from the EARSS 
interactive database [www.rivm.nl/earss]
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